Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | F13A1 | P00488 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 2/20 | 0.47 |
| ▸ | TGM1 | P22735 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309817 | 0.93 | MCL1 (0.43) | EPHX2F13A1TGM2TGM1NR1H2 | |
| SCHEMBL309949 | 0.90 | EPHX2 (0.50) | EPHX2F13A1TGM2TGM1NR1H2 | |
| SCHEMBL308879 | 0.88 | EPHX2 (0.50) | EPHX2NR1H2NR1H3MCL1HSD11B1 | |
| SCHEMBL2832484 | 0.87 | EPHX2 (0.48) | EPHX2GAATRPV4USP2TSHR | |
| SCHEMBL12965416 | 0.86 | F13A1 (0.48) | EPHX2F13A1TGM2TGM1NR1H2 | |
| SCHEMBL309655 | 0.86 | F13A1 (0.48) | EPHX2F13A1TGM2TGM1NR1H2 | |
| SCHEMBL1430098 | 0.84 | F13A1 (0.46) | EPHX2F13A1TGM2TGM1NR1H2 | |
| SCHEMBL308445 | 0.84 | F13A1 (0.46) | EPHX2F13A1TGM2TGM1NR1H2 | |
| SCHEMBL10042197 | 0.82 | TDP1 (0.55) | EPHX2F13A1TGM2TGM1GAA | |
| SCHEMBL2831496 | 0.80 | IDH1 (0.44) | EPHX2GAAUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093249-B2 | Pyrazolo[1,5-A]pyrimidine-carbonyl-piperazine derivatives | Convergence Pharmaceuticals Limited (GB) | 2012-01-10 | — | — | US | disclosed |
| US-20100016330-A1 | Novel Derivatives | Convergence Pharmaceuticals Limited (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016330-A1 | Novel Derivatives | CACNB2, CACNA1B, CACNA1D | EPHX2 3915/4885F13A1 4570/4885TGM2 2597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.